Abstract 3046: The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression
Camille Lafront,Lucas Germain,Gabriel H. Campolina-Silva,Cindy Weidmann,Line Berthiaume,Hélène Hovington,Hervé Brisson,Cynthia Jobin,Lilianne Frégeau-Proulx,Raul Cotau,Kevin Gonthier,Aurélie Lacouture,Patrick Caron,Claire Ménard,Chantal Atallah,Julie Riopel,Éva Latulippe,Alain Bergeron,Paul Toren,Chantal Guillemette,Martin Pelletier,Yves Fradet,Clémence Belleannée,Frédéric Pouliot,Louis Lacombe,Éric Lévesque,Étienne Audet-Walsh
DOI: https://doi.org/10.1158/1538-7445.am2024-3046
IF: 11.2
2024-04-04
Cancer Research
Abstract:Just as the androgen receptor (AR), the estrogen receptor α (ERα) is expressed in the prostate and is thought to influence prostate cancer (PCa) biology. Yet, the incomplete understanding of ERα cellular functions in PCa hinders our ability to fully comprehend its clinical relevance and restricts the repurposing of estrogen-targeted therapies for treatment of this disease. Using two human PCa tissue microarray cohorts, we first demonstrated that nuclear ERα expression was heterogeneous between patients, being only detected in half of tumors. Positive nuclear ERα levels were correlated with disease recurrence, progression to metastatic PCa, and patient survival. Using in vitro and in vivo models of the normal prostate and PCa, bulk and single cell RNA-seq analyses revealed that estrogens partially mimic the androgen transcriptional response and induce specific biological pathways linked to cellular proliferation and metabolism. Bioenergetic flux assays and metabolomics confirmed regulation of cancer metabolism by estrogens, supporting proliferation. Using cancer cell lines and patient-derived organoids, selective estrogen receptor modulators, a pure anti-estrogen, and genetic approaches impaired cancer cell proliferation and growth in an ERα-dependent manner. Overall, our study revealed that, when expressed, ERα functionally reprograms PCa metabolism, is associated with disease progression, and could be targeted for therapeutic purposes. Citation Format: Camille Lafront, Lucas Germain, Gabriel H. Campolina-Silva, Cindy Weidmann, Line Berthiaume, Hélène Hovington, Hervé Brisson, Cynthia Jobin, Lilianne Frégeau-Proulx, Raul Cotau, Kevin Gonthier, Aurélie Lacouture, Patrick Caron, Claire Ménard, Chantal Atallah, Julie Riopel, Éva Latulippe, Alain Bergeron, Paul Toren, Chantal Guillemette, Martin Pelletier, Yves Fradet, Clémence Belleannée, Frédéric Pouliot, Louis Lacombe, Éric Lévesque, Étienne Audet-Walsh. The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3046.
oncology